113 results
DEFA14A
ATXI
Avenue Therapeutics Inc
25 Jan 19
Additional proxy soliciting materials
1:56pm
) (collectively, the “Merger Litigation”). The complaints, which were filed by purported Company stockholders, generally allege that the preliminary … believes that the claims asserted in the Merger Litigation are without merit and that no supplemental disclosure is required under applicable law. However
10-Q
2017 Q1
ATXI
Avenue Therapeutics Inc
12 May 17
Quarterly report
12:00am
to any leases for office space or equipment.
Litigation
The Company recognizes a liability for a contingency when it is probable that liability has been … , there was no litigation against the Company.
Note 8 - Stockholders’ Deficit
Class A Preferred Shares
Pursuant to the Company’s Second Amended
8-K
ATXI
Avenue Therapeutics Inc
5 Apr 21
Departure of Directors or Certain Officers
4:49pm
and biotechnology companies. Prior to Fulcrum Therapeutics, Inc, he served as Vice President, Head of Litigation at DaVita Kidney Care, Inc. where he led a 30 … -person team and was responsible for all litigation, workers’ compensation and employee safety matters. Prior to DaVita Kidney Care, Mr. Oltmans
10-12G
eg26t tev
30 Dec 15
Registration of securities
12:00am
10-K
ihrv98ro27k8w
1 Mar 18
Annual report
12:00am
10-12G
ggr824yfjyfluz6h q5
12 Jan 17
Registration of securities
12:00am
10-12G/A
lf6qe1p
6 Mar 17
Registration of securities (amended)
12:00am
10-12G/A
od0p7s luh
18 Feb 16
Registration of securities (amended)
12:00am